JP2008520548A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008520548A5 JP2008520548A5 JP2007535772A JP2007535772A JP2008520548A5 JP 2008520548 A5 JP2008520548 A5 JP 2008520548A5 JP 2007535772 A JP2007535772 A JP 2007535772A JP 2007535772 A JP2007535772 A JP 2007535772A JP 2008520548 A5 JP2008520548 A5 JP 2008520548A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- amino acid
- group
- residue
- acid residue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims 68
- 125000000539 amino acid group Chemical group 0.000 claims 32
- 210000004027 cell Anatomy 0.000 claims 16
- PCSMJKASWLYICJ-UHFFFAOYSA-N Succinic aldehyde Chemical compound O=CCCC=O PCSMJKASWLYICJ-UHFFFAOYSA-N 0.000 claims 15
- 239000002246 antineoplastic agent Substances 0.000 claims 15
- 229940127089 cytotoxic agent Drugs 0.000 claims 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 13
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 125000003277 amino group Chemical group 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 9
- 125000004432 carbon atom Chemical group C* 0.000 claims 9
- 125000004430 oxygen atom Chemical group O* 0.000 claims 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 8
- 125000003712 glycosamine group Chemical group 0.000 claims 7
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims 5
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims 5
- 229930012538 Paclitaxel Natural products 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 5
- 150000002016 disaccharides Chemical group 0.000 claims 5
- 229960004679 doxorubicin Drugs 0.000 claims 5
- 208000015181 infectious disease Diseases 0.000 claims 5
- 150000002772 monosaccharides Chemical group 0.000 claims 5
- 229960001592 paclitaxel Drugs 0.000 claims 5
- 239000000126 substance Substances 0.000 claims 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 5
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 4
- 229930182830 galactose Natural products 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 244000005700 microbiome Species 0.000 claims 4
- 229960003048 vinblastine Drugs 0.000 claims 4
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 4
- 229960004528 vincristine Drugs 0.000 claims 4
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 4
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 4
- 241000894006 Bacteria Species 0.000 claims 3
- 241000233866 Fungi Species 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 244000045947 parasite Species 0.000 claims 3
- 210000004881 tumor cell Anatomy 0.000 claims 3
- 241001465754 Metazoa Species 0.000 claims 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims 2
- 150000001576 beta-amino acids Chemical group 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000002458 infectious effect Effects 0.000 claims 2
- -1 phospho group Chemical group 0.000 claims 2
- 238000003786 synthesis reaction Methods 0.000 claims 2
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 claims 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 108010078791 Carrier Proteins Proteins 0.000 claims 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 1
- 206010059866 Drug resistance Diseases 0.000 claims 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 108700041567 MDR Genes Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 1
- 210000004102 animal cell Anatomy 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 229960002442 glucosamine Drugs 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000036457 multidrug resistance Effects 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 claims 1
- 150000002482 oligosaccharides Chemical class 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61611404P | 2004-10-06 | 2004-10-06 | |
| PCT/US2005/035795 WO2006041902A2 (en) | 2004-10-06 | 2005-10-06 | Use of nordihydroguaiaretic acid derivatives in the treatment of drug resistant cancer, viral and microbial infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008520548A JP2008520548A (ja) | 2008-06-19 |
| JP2008520548A5 true JP2008520548A5 (enExample) | 2008-11-20 |
Family
ID=36148866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007535772A Withdrawn JP2008520548A (ja) | 2004-10-06 | 2005-10-06 | 薬剤耐性癌、薬剤耐性ウイルス感染症および薬剤耐性微生物感染症におけるノルジヒドログアヤレト酸誘導体の使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20080207532A1 (enExample) |
| EP (1) | EP1848418A4 (enExample) |
| JP (1) | JP2008520548A (enExample) |
| CN (1) | CN101437505A (enExample) |
| AU (1) | AU2005294432A1 (enExample) |
| CA (1) | CA2583336A1 (enExample) |
| MX (1) | MX2007004025A (enExample) |
| WO (1) | WO2006041902A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008027337A2 (en) * | 2006-08-28 | 2008-03-06 | The Ohio State University Research Foundation | Compositions for reducing cell adhesion to bubbles |
| US8178527B2 (en) * | 2006-10-02 | 2012-05-15 | Erimos Pharmaceuticals Llc | Tetra-substituted NDGA derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use |
| SI2134374T1 (sl) * | 2007-03-14 | 2014-03-31 | Bionsil S.R.L. In Liquidazione | Inhibitorji btk za rabo pri zdravljenju na kemoterapevtska zdravila rezistentnih epitelijskih tumorjev |
| EP2240168B1 (en) * | 2008-01-08 | 2014-05-14 | The Johns Hopkins University | Suppression of cancer growth and metastasis using nordihydroguaiaretic acid derivatives with metabolic modulators |
| US20100093872A1 (en) * | 2008-10-15 | 2010-04-15 | Erimos Pharmaceuticals Llc | Stable aqueous formulations of water insoluble or poorly soluble drugs |
| US8710104B2 (en) | 2008-11-07 | 2014-04-29 | Triact Therapeutics, Inc. | Catecholic butanes and use thereof for cancer therapy |
| EP2538935B1 (en) | 2010-02-22 | 2014-11-05 | The Johns Hopkins University | Suppression of cancer growth and metastasis using nordihydroguaiaretic acid derivatives with 7-hydroxystaurosporine |
| WO2012145575A2 (en) * | 2011-04-21 | 2012-10-26 | Children's Hospital Medical Center | Therapy for leukemia |
| US10342767B2 (en) | 2011-04-21 | 2019-07-09 | Children's Hospital Medical Center | Therapy for kinase-dependent malignancies |
| US9084779B2 (en) | 2011-05-31 | 2015-07-21 | The Johns Hopkins University | Conjugates of nitroimidazoles and their use as chemotherapeutic agents |
| SG11201404542TA (en) * | 2012-02-03 | 2014-10-30 | Univ Johns Hopkins | Compositions comprising ndga derivatives and sorafenib and their use in treatment of cancer |
| JP6255038B2 (ja) * | 2013-02-26 | 2017-12-27 | トリアクト セラピューティクス，インク． | 癌治療 |
| GB201307989D0 (en) * | 2013-05-02 | 2013-06-12 | Helperby Therapeutics Ltd | Novel combinations and use |
| CA2923667A1 (en) | 2013-09-09 | 2015-03-12 | Triact Therapeutics, Inc. | Cancer therapy |
| CN105902526A (zh) * | 2016-05-06 | 2016-08-31 | 兰州大学 | 马索罗酚在制备治疗包虫病的药物中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0289506A4 (en) * | 1986-11-19 | 1990-12-12 | Chemex Pharmaceuticals, Inc. | Lipoxygenase inhibitors |
| US5409690A (en) * | 1993-06-23 | 1995-04-25 | Chemex Pharmaceuticals, Inc. | Treatment of multidrug resistant diseases in cancer cell by potentiating with masoprocol |
| US6214874B1 (en) * | 1999-10-15 | 2001-04-10 | John Hopkins University | Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N |
| WO2006014669A2 (en) * | 2004-07-20 | 2006-02-09 | Erimos Pharmaceuticals Llc | Methods and compositions for treatment of intraepithelial neoplasia |
-
2005
- 2005-10-06 US US11/664,875 patent/US20080207532A1/en not_active Abandoned
- 2005-10-06 MX MX2007004025A patent/MX2007004025A/es not_active Application Discontinuation
- 2005-10-06 EP EP05816163A patent/EP1848418A4/en not_active Withdrawn
- 2005-10-06 CN CNA2005800400639A patent/CN101437505A/zh active Pending
- 2005-10-06 WO PCT/US2005/035795 patent/WO2006041902A2/en not_active Ceased
- 2005-10-06 AU AU2005294432A patent/AU2005294432A1/en not_active Abandoned
- 2005-10-06 CA CA002583336A patent/CA2583336A1/en not_active Abandoned
- 2005-10-06 JP JP2007535772A patent/JP2008520548A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008520548A5 (enExample) | ||
| Lu et al. | Redox/pH dual-controlled release of chlorhexidine and silver ions from biodegradable mesoporous silica nanoparticles against oral biofilms | |
| JP7305613B2 (ja) | 併用がん療法 | |
| AU2009308182B2 (en) | Biodefenses using triazole-containing macrolides | |
| EP2127652B1 (en) | Method for treating cancer using anticancer agent in combination | |
| JP7013369B2 (ja) | Ｅｚｈ２阻害剤により卵巣の悪性ラブドイド腫瘍（ｍｒｔｏ）／高カルシウム血症型の卵巣の小細胞癌（ｓｃｃｏｈｔ）を処置するための方法 | |
| TWI759301B (zh) | 聚乙二醇化卡非佐米化合物 | |
| AU754489B2 (en) | Acid labile prodrugs | |
| EP2616065B1 (en) | Glyco-substituted dihydroxy-chlorins and b-functionalized chlorins for anti-microbial photodynamic therapy | |
| JP2002003408A (ja) | 核医学映像の撮像のためのまたは磁気共鳴映像におけるコントラストの増強のための剤 | |
| EP3606559A1 (en) | Bioorthogonal compositions | |
| RU2008142957A (ru) | Способы получения функционального белка из днк, имеющей нонсенс-мутацию, и лечения нарушений, ассоциированных с ней | |
| CN1507869A (zh) | 含吗啉蒽环类化生物和抗癌剂的联合制剂 | |
| CN1536995A (zh) | 含有紫杉烷衍生物的抗肿瘤组合物 | |
| JP2016502981A (ja) | ムチンが関与する疾患の処置 | |
| Fan et al. | Enantioselective antiviral activities of chiral zinc oxide nanoparticles | |
| JP2008520548A (ja) | 薬剤耐性癌、薬剤耐性ウイルス感染症および薬剤耐性微生物感染症におけるノルジヒドログアヤレト酸誘導体の使用 | |
| TWI454280B (zh) | Pharmaceutical composition or combination | |
| JP2017193591A (ja) | 腫瘍細胞選択的抗がん剤 | |
| HK1054193A1 (en) | Use of substituted acryloyl distamycin derivatives in the treatment of tumors associated with high levels of glutathione | |
| EE05090B1 (et) | Tsklipostiinihend kasutamiseks diabeedivastase ravimina, seda sisaldav farmatseutiline preparaat,hendi ja preparaadi valmistamine ning selleks vajalik mikroorganism | |
| CN112638922B (zh) | 金(iii)配合物、其缀合物、包含其的药物组合物以及用途和制备其的方法 | |
| Potmesil et al. | Effects of N-trifluoroacetyladriamycin-14-O-hemiadipate and radiation on L1210 cells | |
| US12303508B2 (en) | Combinatory treatment strategies of cancer based on RNA polymerase I inhibition | |
| JP6041360B2 (ja) | 抗菌性光線力学療法のための、糖−置換ジヒドロキシ−クロリン及びβ−官能化クロリン |